PR 879-317A enhances in vitro immune activity of peripheral blood mononuclear cells from patients with Down syndrome.
Down syndrome is associated with immune deficiencies which result in increased incidences of respiratory infections and lymphocytic leukemia. Peripheral blood mononuclear cells (PBMC) from patients with Down Syndrome were assayed in several in vitro assays following incubation in medium or various concentrations of PR 879-317A (2,3,5,6,7,8-hexahydro-2-phenyl-8,8-dimethoxyimidazo (1,2a) pyridine), a selective immunorestorative agent. PBMC of the patients, incubated in medium, exhibited significantly reduced activities in the natural killer (NK) cell, antibody-dependent cell-mediated cytotoxicity (ADCC), T-cell blastogenesis and leukocyte-inhibition factor (LIF) assays. Incubation in PR 879-317A significantly increased the NK and ADCC activities of PBMC from both patients and healthy subjects. However, the effect was much more pronounced on the patients' cells increasing their NK and ADCC activities to normal levels. Incubation in PR 879-317A augmented to normal levels the responses of patients' cells in various assessments of T-cell immunity including blastogenic responses to phytohemagglutinin and concanavalin A and production of LIF. In addition, the number of patients' cells forming spontaneous rosettes with sheep red blood cells was increased following incubation in PR 879-317A. In contrast this compound did not significantly modify the T-cell responses of cells from the healthy subjects suggesting that this compound does not affect normal T-cell function.